• 1. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Comprehensive Guide to 4-Methylumbelliferyl 2-Acetamido-2-deoxy-α-D-galactopyranoside (CAS No. 124223-99-0): Applications and Insights

4-Methylumbelliferyl 2-Acetamido-2-deoxy-α-D-galactopyranoside (CAS No. 124223-99-0) is a specialized fluorogenic substrate widely used in biochemical and enzymatic research. This compound, often abbreviated as 4-MU-α-GalNAc, is a derivative of 4-methylumbelliferone (4-MU), a well-known fluorophore. Its unique structure makes it invaluable for detecting and quantifying α-N-acetylgalactosaminidase activity, a critical enzyme in glycobiology and lysosomal storage disorder studies.

In recent years, the demand for fluorogenic substrates like 4-MU-α-GalNAc has surged due to their role in high-throughput screening (HTS) and diagnostic assays. Researchers are increasingly focusing on enzyme kinetics and glycosidase inhibition, driven by the growing interest in precision medicine and biomarker discovery. The compound’s ability to emit fluorescence upon enzymatic cleavage allows for sensitive and real-time monitoring, making it a staple in clinical diagnostics and drug development.

One of the most searched topics related to 4-Methylumbelliferyl 2-Acetamido-2-deoxy-α-D-galactopyranoside is its application in Fabry disease research. Fabry disease, a rare lysosomal storage disorder, is characterized by deficient α-galactosidase A activity. While 4-MU-α-GalNAc is not a direct substrate for this enzyme, its structural analogs are often used to study related pathways. This connection has sparked interest in enzyme replacement therapy (ERT) and small-molecule chaperones, aligning with the broader trend of rare disease research.

From a technical perspective, 4-MU-α-GalNAc is prized for its high sensitivity and low background noise in fluorescence-based assays. Its excitation and emission maxima (~360 nm and ~450 nm, respectively) are compatible with standard laboratory equipment, facilitating its adoption in academic and industrial settings. Moreover, the compound’s stability under typical assay conditions ensures reproducible results, a key factor in GMP-compliant environments.

The rise of AI-driven drug discovery has also impacted the use of fluorogenic substrates. Computational models often rely on enzymatic activity data generated using compounds like 4-MU-α-GalNAc, bridging the gap between in silico predictions and wet-lab validation. This synergy underscores the compound’s relevance in modern biopharmaceutical research.

In summary, 4-Methylumbelliferyl 2-Acetamido-2-deoxy-α-D-galactopyranoside (CAS No. 124223-99-0) is a versatile tool with applications spanning diagnostics, drug discovery, and glycobiology. Its alignment with cutting-edge research trends, such as rare disease therapeutics and AI-aided development, ensures its continued importance in the scientific community.

• 37067-30-4(4-Methylumbelliferyl 2-Acetamido-2-deoxy-b-D-glucopyranoside)
• 9001-67-6(Neuraminidase (9CI, ACI))
• 36476-29-6(4-Methylumbelliferyl 2-Acetamido-2-deoxy-b-D-galactopyranoside)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)